May 21, 2018 / 7:23 PM / in a month

BRIEF-Urogen Pharma Announces Positive Interim Results From Pivotal Phase 3 Olympus Trial Of UGN-101

May 21 (Reuters) - Urogen Pharma Ltd:

* UROGEN PHARMA ANNOUNCES POSITIVE INTERIM RESULTS FROM PIVOTAL PHASE 3 OLYMPUS TRIAL OF UGN-101 (MITOGEL™) FOR NON-SURGICAL TREATMENT OF UPPER TRACT UROTHELIAL CANCER (UTUC)

* UROGEN PHARMA LTD - INTERIM RESULTS SHOWED COMPLETE RESPONSE (CR) RATE OF 59 PERCENT IN PATIENTS WITH LOW-GRADE UTUC

* UROGEN PHARMA LTD - OLYMPUS TRIAL CONTINUES TO ENROLL PATIENTS, AND TOP-LINE RESULTS ARE EXPECTED IN SECOND HALF OF 2018

* UROGEN PHARMA LTD - CRS TO DATE REMAIN DURABLE AT THREE, SIX AND NINE-MONTH FOLLOW-UP IN PHASE 3 OLYMPUS TRIAL OF UGN-101

* UROGEN PHARMA LTD - UGN-101 APPEARED TO BE WELL-TOLERATED WITH MOST TREATMENT-EMERGENT ADVERSE EVENTS CHARACTERIZED AS MILD OR MODERATE AND TRANSIENT Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below